Previous 10 | Next 10 |
Despite starting the year off strong, biotech stocks have had a rough summer. The recent weakness in the biotech sector is causing biotech exchange-traded funds (ETFs) like the VanEck Vectors Biotech ETF (BBH), the iShares NASDAQ Biotechnology ETF (IBB), and the SPDR S&P Bio...
Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2019 financial results will be released on Wednesday, October 30, 2019 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. P...
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
Acadia Pharmaceuticals (NASDAQ: ACAD) , Amarin (NASDAQ: AMRN) and Exelixis (NASDAQ: EXEL) check the boxes for what investors should look for in a promising biotech company: compelling drugs, increasing sales, near-term catalysts, and the possibility of being acquired. Like Goldilocks ...
– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, which is being held next week in New York. Exelixis...
NetworkNewsWire Editorial Coverage : Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the...
– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the Morgan Stanley 17 th Annua...
Cancer treatment is one of the hottest areas of healthcare investing these days, with personalized medicine like genetic therapies providing new promises of treatment and potential cures. Still, despite the progress that researchers have made, there are still plenty of false starts and treatme...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...